Xie Wei, Wang Sa A, Hu Shimin, Xu Jie, Medeiros L Jeffrey, Tang Guilin
Department of Hematopathology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA.
Department of Hematopathology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA.
Cancer Genet. 2018 Dec;228-229:41-46. doi: 10.1016/j.cancergen.2018.08.002. Epub 2018 Aug 27.
Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized. To date, less than 20 cases of ABL1-ETV6+ MPN have been reported. We report a 47-year-old man who presented with MPN with clinicopathologic features resembling chronic myeloid leukemia, but there was no evidence of t(9;22)(p34.1;q11.2) or BCR-ABL1 fusion. Conventional cytogenetics and fluorescence in situ hybridization analysis showed ins(12;9)(p13;q34q34) that led to ETV6-ABL1 fusion. The patient responded well to tyrosine kinase inhibitor therapy and achieved remission for 7 years.
与ABL1-ETV6融合相关的骨髓增殖性肿瘤(MPN)较为罕见,其特征也鲜为人知。迄今为止,报道的ABL1-ETV6阳性MPN病例不足20例。我们报告了一名47岁男性,他患有MPN,其临床病理特征类似于慢性髓性白血病,但没有t(9;22)(p34.1;q11.2)或BCR-ABL1融合的证据。传统细胞遗传学和荧光原位杂交分析显示存在ins(12;9)(p13;q34q34),导致ETV6-ABL1融合。该患者对酪氨酸激酶抑制剂治疗反应良好,缓解达7年。